Negative views toward agonists manifest in tapering, feelings of mistrust.

Even in service settings that accept the use of methadone and buprenorphine as part of treatment, stigmatizing attitudes toward the medications' role can result in treatment decisions that conflict with medical guidelines, suggests a paper based on interviews with providers and drug users. The authors suggest that these views are shaped in part by some providers' mistrust of patients with opioid use disorder (OUD) and their own experiences with non‐agonist paths to recovery. Methadone is a full opioid agonist; buprenorphine is a partial agonist. [ABSTRACT FROM AUTHOR]